MnetTV          Digital Library

Search Manufacturing.net Search Manufacturing.net


Resources
Association Links
Bookstore
Career Center
Digital Library
Events Calendar
What’s New
White Papers


News
Featured Articles
Financial News
Global Manufacturing
Government News
Mergers & Acquisitions
News Archive
People in the News

MNet Career Center

Market Sectors
Aerospace
Automotive/Transportation
Chemical/Petroleum
Food/Beverage
Medical
Metals
Pharmaceuticals/Biotech
Plastics/Rubber
Other Manufacturing

Industry Focus
Design & Development
Electrical & Electronics
Energy
Environmental
Facilities & Operations
Labor Relations
Manufacturing Technology
Materials
Quality
Safety
Supply Chain

Amazon

About Us
Editorial Contacts
Advertise with Us

Our Partner Sites
Chem.Info
ECN
Food Manufacturing
IMPO (Industrial Maintenance & Plant Operation)
Medical Design Technology
Pharmaceutical Processing
Product Design & Development
R & D Magazine
Wireless Design & Development
Wireless Week



Cure For OTC Industry 's Small Manufacturers: Rx-To-OTC Switches
By Anita LaFond, News Editor, Manufacturing.net
Manufacturing.Net - September 07, 2006

Printer Friendly     E-mail to a Colleague


Recent consolidations in the OTC industry have accounted for more than half of the total sales volume being realized by just 10 manufacturers, according to the Kline & Company's latest study, "NONPRESCRIPTION DRUGS USA 2005."

Although sales of nonprescription drugs in the U.S. grew by only 3% in 2005, some of the biggest manufacturers in the OTC market continued to increase their dominance.

"Drug manufacturers are seeking big consolidation deals and seem to be following in the footsteps of the major drug retailers like Rite Aid, which acquired Brooks and Eckerd last week," said Laura Mahecha, industry manager of the Healthcare practice for Kline's research division. "The drug companies are playing catch-up to the retailers by growing their portfolios in order to better serve the larger retailers."

If Johnson & Johnson's acquisition of Pfizer's OTC division comes to fruition, J&J's share of the market could approach 20%. But to get the approval of regulators, J&J will probably have to divest more than a few brands.

"For smaller and mid-sized companies, this is a great chance to add big-name brands to their product mix at fair prices as the major players divest brands in order to gain merger approval," Mahecha said.

A big market boost could come from Rx-to-OTC switches.

"Part of the J&J merger includes OTC rights to Zyrtec from Pfizer, and GlaxoSmithKline already has OTC rights to Roche's Xenical anti-obesity drug, which could be a real groundbreaking event if the switch is approved," explained Mahecha.
 
While the current consolidation trends could seem problematic for smaller manufacturers, it could actually help in the development of niche markets.

"Smaller and mid-sized companies will finally have a chance to acquire these divested brands, where they couldn't even touch them before," said Susan Babinsky, senior vice president and head of Kline's Consumer Products consulting practice. "These acquisitions can turn into great opportunities for smaller companies armed with compelling and focused strategic plans to grow these brands."


Printer Friendly     E-mail to a Colleague




 

     



   





Flatbed trucking, flatbed shipping, flatbed carriers



Food/Beverage

Kraft Closing UK Cadbury Plant

Overseas Sales Help Coca-Cola 4Q Profit

Green Mountain Extends Diedrich Coffee Offer


Pharmaceuticals/Biotech

Bristol-Myers Squibb Freezing Salaries

Former Bristol-Myers Worker Charged With Trade Theft

GlaxoSmithKline Profit Rises 66 Percent

Metals

Rio Tinto Sells Ghana Bauxite Stake To Chinese Firm

Cadmium Found In Adult Jewelry

Alcoa Realigns Business Units, Adds COOs
News Video